| Message from the CEO
Welcome to Lantheus Medical Imaging and thank you for taking the time to learn more about our company. As a worldwide leader in diagnostic imaging for the past 50 years, we remain committed to our customers and patients and making important investments to continue to elevate the field of medical imaging. We are excited about the future of our company as we expand on our proud heritage of providing innovative diagnostic imaging products that illuminate the heart and other organs. We encourage you to learn more about Lantheus Medical Imaging, our people, products and pipeline.
Lantheus Updates
Molybdenum-99 Supply Statement from Lantheus Medical Imaging
As a Technetium-99m (Tc-99m) generator manufacturer, we are one part of a very complex supply chain. We are working with our suppliers to obtain Molybdenum-99 (Mo-99) during this current shortage. The amount of Mo-99 we receive over the course of this outage will vary day by day. read more
|
|
News
07/15/10
Lantheus Medical Imaging, Inc. Launches DEFINITY® Ultrasound Contrast Imaging Agent in India
07/12/10
Lantheus Medical Imaging, Inc. Purchases Balance of Worldwide Rights for MRA Imaging Agent ABLAVAR® (Gadofosveset Trisodium)
07/08/10
Lantheus Medical Imaging, Inc. Announces Agreement with MDS Nordion to Secure Additional Supply of Molybdenum-99 (Mo-99), a Key Medical Isotope
06/14/10
Lantheus Medical Imaging, Inc. Presents Phase 4 Safety Data on DEFINITY® at American Society of Echocardiography Annual Meeting
06/09/10
Lantheus Medical Imaging, Inc. Presents Preliminary Data on Novel PET Myocardial Perfusion Imaging Agent Protocol at SNM Annual Meeting
06/09/10
Lantheus Medical Imaging, Inc. Recognized as Top-Performing Supplier
by Premier Purchasing Partners, L.P.
|
|
Company Spotlight
Lantheus Medical Imaging, Inc. Launches DEFINITY® Ultrasound Contrast Imaging Agent in India
-- Company Expands Global Presence and Access to DEFINITY®
With Distributor J.B. Chemicals & Pharmaceuticals, Ltd. --
N. BILLERICA, Mass. (July 15, 2010) – Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the launch of its ultrasound contrast imaging agent, DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, in India. The company has signed a multi-year agreement with Mumbai-based J.B. Chemicals & Pharmaceuticals, Ltd. (“JBCPL”) for the distribution and marketing of DEFINITY® in the Indian marketplace. The launch expands Lantheus’ presence in southern Asia. DEFINITY® is currently marketed in North America, Australia and New Zealand, parts of the Pacific Rim, and several countries in the Middle East.
click here for the press release
Lantheus Medical Imaging, Inc. Presentation at Jefferies 2010 Global Life Sciences Conference
Don Kiepert, President and Chief Executive Officer
June 9, 2010
View Archived Presentation
|
